This ESMO Clinical Practice Guideline (CPG) focuses on advanced and metastatic prostate cancer. This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC). The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer.1
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
Annals of Oncology | | K. Fizazi, G. Attard, A.A. Azad, G. Baciarello, H. Beltran, A. Bjartell, P. Blanchard, F. Bossaert, E. Castro, E. Compérat, J. de Bono, A. Deschamps, E. Efstathiou, L. Emmett, S. Fanti, V. Fonteyne, A. González-del-Alba, G. Gravis, N.D. James, R. Kanesvaran, R.S. McDermott, N. Mehra, C. Parker, R.M. Renard-Penna, M.A. Rubin, F. Saad, C. Sweeney, D. Tilki, B. Tombal, A.C. Tree, J. Walz, T. Zilli, S. Gillessen, ESMO Guidelines Committee
Topics: prostate-cancer